Gufic Biosciences to launch Botulinum Neuromedicine in India
Mumbai: Gufic Biosciences Limited ("the Company") recently announced to launch Botulinum Neurotoxin in India in collaboration with USA based Company Prime Bio, Inc., led by Dr Bal Ram Singh. The Company has received regulatory approval to manufacture and market Botulinum Neurotoxin.
The Company is an indigenous manufacturing company to launch such project in India with a robust and inherent world-class infrastructure which will help the Company to bring the cost-effective option of this toxin to India and also expand them to middle east, East and Southeast Asia.
Botulinum Neurotoxin is provided by a kind of bacteria called as clostridium botulinum. Botulinum Neurotoxin is used in therapeutic and aesthetic procedures. Some of the Clinical Uses are Movement Disorders, Spasticity, Pain Syndromes, Cosmetics.
There are a total 137 disorders for which clinical data is available.
Read Also: HC pulls up Pharma co for violating court orders, directs it to plant 33,000 more saplings
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd